# IIT2025-03-YANG-LIFT-HCC

> **NCT07489976** · PHASE2 · RECRUITING · sponsor: **Ju Dong Yang** · enrollment: 41 (estimated)

## Conditions studied

- Hepato Cellular Carcinoma

## Interventions

- **DRUG:** STRIDE Regimen (Tremelimumab 300 mg AND Durvalumab 1500 mg) combined with LRT (TACE, TARE, or RFA)

## Key facts

- **NCT ID:** NCT07489976
- **Lead sponsor:** Ju Dong Yang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2030-04-01
- **Final completion:** 2030-12-31
- **Target enrollment:** 41 (ESTIMATED)
- **Last updated:** 2026-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07489976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07489976, "IIT2025-03-YANG-LIFT-HCC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07489976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*